Seminal immunologic discoveries with direct clinical implications: The 2018 Nobel Prize in Physiology or Medicine honours discoveries in cancer immunotherapy
Authors:
- 28 November 2018
- journal article
- editorial
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 88 (6) , e12731
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- T‐cell cross‐reactivity may explain the large variation in how cancer patients respond to checkpoint inhibitorsScandinavian Journal of Immunology, 2018
- Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian CancerJournal of Clinical Oncology, 2015
- Single‐institution experience with ipilimumab in advanced melanoma patients in the compassionate use settingCancer, 2010
- PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cellsInternational Immunology, 2004
- Enhancement of Antitumor Immunity by CTLA-4 BlockadeScience, 1996
- CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.Journal of Experimental Medicine, 1995
- Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.The EMBO Journal, 1992